Arcutis Biotherapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€227.38M - Cost of goods sold
€24.80M - Gross profit
€202.58M - SG&A expenses
€215.41M - R&D expenses
€61.26M - EBITDA
-€59.14M - D&A
€4.82M - EBIT
-€74.08M - Interest expenses
€15.72M - EBT
-€79.68M - Tax expenses
€814.71K - Net income
-€80.50M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€21.78M - Changes in working capital
€7.03M - Operating cash flow
-€56.52M - Capex
€5.03M - Other investing cash flow
-€8.63M - Net investing cash flow
€128.44M - Total cash dividends paid
€0.00 - Issuance of common stock
-€1.33M - Debt repayment
€0.00 - Other financing cash flow
-€83.34M - Net financing cash flow
-€82.20M - Foreign exchange effects
€58.69K - Net change in cash
-€10.22M - Cash at end of period
€63.04M - Free cash flow
-€51.49M
Balance sheet
- Cash and cash equivalents
€63.04M - Cash and short-term investments
€164.95M - Total receivables
€92.08M - Inventory
€14.09M - Other current assets
€16.08M - Total current assets
€287.20M - Property, plant & equipment
€2.69M - Goodwill
€0.00 - Intangible assets
€13.75M - Long-term investments
€0.00 - Other non-current assets
€514.37K - Total non-current assets
€16.96M - Total assets
€304.16M - Accounts payable
€13.02M - Short-term debt
€863.04K - Other current liabilities
€75.82M - Total current liabilities
€89.70M - Long-term debt
€94.21M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€310.69K - Total non-current liabilities
€94.52M - Total liabilities
€184.22M - Common stock
€10.36K - Retained earnings
-€1.00B - Other equity
-€30.21K - Total equity
€119.94M - Total liabilities and shareholders' equity
€304.16M
Company information
- Market capitalization
€1.40B - Employees
342 - Enterprise Value
€1.69B
Company ratios
- Gross margin
-
89.1% Much better than peer group: -29,281.1% - EBITDA margin
-
-26.0% Much better than peer group: -41,247.8% - EBIT margin
-
-32.6% Much better than peer group: -41,564.7% - EBT margin
-
-35.0% Much better than peer group: -41,937.7% - Net margin
-
-35.4% Much better than peer group: -41,925.9% - ROE
-
-67.1% Much worse than peer group: -24.2% - ROA
-
-26.5% Better than peer group: -46.0% - Asset turnover
-
74.8% Much better than peer group: 14.6% - FCF margin
-
-27.1% Much better than peer group: -37,455.8% - FCF yield
-4.4% - Efficiency ratio
126.0% - Net sales per employee
-
€664.85K - Net income per employee
-
-€235.37K